文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

大分割质子推量4次5Gy联合50Gy光子治疗局限期前列腺癌高效

High efficacy of hypofractionated proton therapy with 4 fractions of 5 Gy as a boost to 50 Gy photon therapy for localized prostate cancer.
PubMed 文献 · Radiother Oncol · 2019-08-17

研究报道大分割质子推量替代高剂量率近距离放疗推量治疗局限期前列腺癌各风险组的结果。2002-2015年治疗531例患者,504例局限期,中位随访113个月。低、中、高、极高危5年生化无复发生存率分别为100%、94%、82%、72%,GU 3级+毒性2%,GI 0%。

要点

  • 5年生化无复发生存率低危100%、中危94%、高危82%、极高危72%。
  • 症状-free患者GU 3级+毒性2%,GI 0%,淋巴结治疗未加重毒性。

核心结论

  • 大分割质子推量剂量递增疗效与高剂量率近距离放疗推量相当,GU和GI毒性谱相似。
  • 质子推量也适用于前列腺体积较大、T分期较高和高危疾病并接受选择性区域淋巴结光子治疗的患者。

研究设计与样本

  • 单中心研究,2002-2015年治疗531例患者,其中504例局限期,中位随访113个月(43-193)。

主要发现

  • 低、中、高、极高危患者5年PSA无复发生存率分别为100%、94%、82%、72%。
  • 延长ADT改善生化控制和淋巴结治疗区域控制。
  • NCCN分类比ISUP分类具有更高的预测区分度。
  • 治疗前无症状患者5年GU 3级+毒性发生率为2%,GI为0%,淋巴结治疗未加重毒性。

关键数值与推荐

  • 高危/极高危患者中多数接受ADT 9-24个月,92例接受辅助盆腔淋巴结治疗。

临床怎么用

  • 可将大分割质子推量作为高剂量率近距离放疗推量的替代方案。
  • 适用于前列腺体积较大、T分期较高和高危患者,可联合选择性区域淋巴结光子治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report the outcome of hypofractionated proton boost as an alternative to high dose-rate brachytherapy boost, aimed at an equivalent dose exceeding 86 Gy in 2 Gy fractions, for patients with localized prostate cancer and all risk groups. METHODS: Proton boost of 20 Gy given in 4 daily fractions to the prostate was followed after a one-week rest by photon therapy to 50 Gy in 2 Gy fractions. Outcomes are presented per risk group according to both NCCN and ISUP classifications. Advanced imaging was performed for adequate staging, and at an early stage of rising PSA, to identify the relapse site. Endpoints were PSA relapse-free-, locoregional relapse-free-, and distant metastasis-free- survival. Prostate cancer-specific-, metastasis-free-, and overall survival were also estimated. Genitourinary (GU) and gastrointestinal (GI) toxicity were based on patients' questionnaires and physicians' records. RESULTS: We treated 531 patients between 2002 and 2015; 504 had localized disease. The cohort included 180 patients with T3/T4 disease (36%). The majority of the 50% with high-/very high-risk disease received ADT, 9-24 months; 92 had adjuvant pelvic node treatment. Median follow-up was 113 months (43-193). For low-, intermediate-, high-, and very high-risk patients, the 5-year PSA relapse-free survival was 100%, 94%, 82%, and 72%, respectively. Prolonged ADT improved biochemical control and nodal treatment regional control. The NCCN classification had higher predictive discrimination than the ISUP classification. The 5-year prevalence grade 3+ was 2% for GU and 0% for GI toxicity in pre-treatment symptom-free patients, and not worsened by nodal treatment. CONCLUSION: Dose escalation with hypofractionated proton boost was as effective as reported with high dose-rate brachytherapy boost, and the GU and GI toxicity profile was very similar. The proton boost was also appropriate for patients with larger prostate volume, higher T-stage, and high-risk disease encompassing elective regional node photon therapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Johansson S, Isacsson U, Sandin F, et al. High efficacy of hypofractionated proton therapy with 4 fractions of 5 Gy as a boost to 50 Gy photon therapy for localized prostate cancer. Radiother Oncol. 2019. PMID: 31431382. doi:10.1016/j.radonc.2019.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。